How AI adoption isn’t translating into market advantage in clinical development

AI is everywhere in clinical development. So why isn’t it creating clearer competitive advantage?

Across pharma and biotech, AI is already embedded into workflows. Teams are using multiple tools across discovery, trial design and operations. Value is being realised, but the impact still feels uneven. To understand why, you have to look at how AI is actually being used today.

The reality: AI is being used, but not fully trusted

Right now, AI in clinical development operates in a ‘trust but verify’ model.

Outputs are validated and sense-checked by experts before they are used, which is an entirely rational process in a regulated environment where the cost of error is high. But it has a knock-on effect in that it limits how far and how fast AI can scale.

More importantly, it limits how much it can differentiate one organization from another. Think about it like this – if every organization:

• Uses similar AI tools
• Applies similar validation processes
• Relies on human oversight to confirm outputs

Then the advantage AI creates starts to flatten.

Work still gets done faster, but decision-making doesn’t necessarily improve at the same rate. Nor does insight deepen or outcomes change. Which means AI rapidly becomes a hygiene factor, not a differentiator.

Why AI isn’t yet a competitive advantage

ISR’s data reinforces this tension; AI adoption is high but at the same time, many organizations lack strategic plans or formal governance frameworks to scale its use effectively.

So what you see in practice is:

• Strong pockets of AI-driven efficiency
• Inconsistent application across teams
• Heavy reliance on manual validation

The messaging gap: Why “AI-powered” isn’t landing

This dynamic also explains something happening at a brand level. Many life science companies have shifted messaging to showcase their AI capabilities or processes, but very few are communicating clear, differentiated value from it.

With ambiguity over how AI is being used and whether it is delivering a measurable advantage, simply claiming “AI-powered” doesn’t carry much weight. Until that’s clear to customers, prospects and investors, AI remains a supporting narrative instead of a defining one.

Where the real opportunity sits

The next phase of AI in clinical development isn’t about more adoption, but operationalisation into a defining competitive advantage.

Specifically, embedding AI into structured, repeatable workflows that align with strategic objectives speaking directly to customer needs. This transforms the somewhat lacklustre “AI-powered” messaging into a compelling narrative that sees your organization pull ahead of competitors.

ISR’s latest report explores how clinical development teams are using AI today, where it’s delivering value, and what’s holding broader impact back.

If you’re looking to understand not just where AI is being used, but how it translates into meaningful impact for your brand, it’s a valuable place to start.